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A Multiscale Computational Approach to Dissect Early Events in the Erb
Family Receptor Mediated Activation, Differential Signaling, and
Relevance to Oncogenic Transformations
Abstract
We describe a hierarchical multiscale computational approach based on molecular dynamics simulations, free
energy-based molecular docking simulations, deterministic network-based kinetic modeling, and hybrid
discrete/continuum stochastic dynamics protocols to study the dimermediated receptor activation
characteristics of the Erb family receptors, specifically the epidermal growth factor receptor (EGFR). Through
these modeling approaches, we are able to extend the prior modeling of EGF-mediated signal transduction by
considering specific EGFR tyrosine kinase (EGFRTK) docking interactions mediated by differential binding
and phosphorylation of different C-terminal peptide tyrosines on the RTK tail. By modeling signal flows
through branching pathways of the EGFRTK resolved on a molecular basis, we are able to transcribe the
effects of molecular alterations in the receptor (e.g., mutant forms of the receptor) to differing kinetic behavior
and downstream signaling response. Our molecular dynamics simulations show that the drug sensitizing
mutation (L834R) of EGFR stabilizes the active conformation to make the system constitutively active.
Docking simulations show preferential characteristics (for wildtype vs. mutant receptors) in inhibitor binding
as well as preferential enhancement of phosphorylation of particular substrate tyrosines over others. We find
that in comparison to the wildtype system, the L834R mutant RTK preferentially binds the inhibitor erlotinib,
as well as preferentially phosphorylates the substrate tyrosine Y1068 but not Y1173. We predict that these
molecular level changes result in preferential activation of the Akt signaling pathway in comparison to the Erk
signaling pathway for cells with normal EGFR expression. For cells with EGFR over expression, the mutant
over activates both Erk and Akt pathways, in comparison to wildtype. These results are consistent with
qualitative experimental measurements reported in the literature. We discuss these consequences in light of
how the network topology and signaling characteristics of altered (mutant) cell lines are shaped differently in
relationship to native cell lines.
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Abstract—We describe a hierarchical multiscale computa-
tional approach based on molecular dynamics simulations,
free energy-based molecular docking simulations, determin-
istic network-based kinetic modeling, and hybrid discrete/
continuum stochastic dynamics protocols to study the dimer-
mediated receptor activation characteristics of the Erb family
receptors, speciﬁcally the epidermal growth factor receptor
(EGFR). Through these modeling approaches, we are able to
extend the prior modeling of EGF-mediated signal trans-
duction by considering speciﬁc EGFR tyrosine kinase
(EGFRTK) docking interactions mediated by differential
binding and phosphorylation of different C-terminal peptide
tyrosines on the RTK tail. By modeling signal ﬂows through
branching pathways of the EGFRTK resolved on a molec-
ular basis, we are able to transcribe the effects of molecular
alterations in the receptor (e.g., mutant forms of the
receptor) to differing kinetic behavior and downstream
signaling response. Our molecular dynamics simulations
show that the drug sensitizing mutation (L834R) of EGFR
stabilizes the active conformation to make the system
constitutively active. Docking simulations show preferential
characteristics (for wildtype vs. mutant receptors) in inhibitor
binding as well as preferential enhancement of phosphory-
lation of particular substrate tyrosines over others. We ﬁnd
that in comparison to the wildtype system, the L834R mutant
RTK preferentially binds the inhibitor erlotinib, as well as
preferentially phosphorylates the substrate tyrosine Y1068
but not Y1173. We predict that these molecular level changes
result in preferential activation of the Akt signaling pathway
in comparison to the Erk signaling pathway for cells with
normal EGFR expression. For cells with EGFR over
expression, the mutant over activates both Erk and Akt
pathways, in comparison to wildtype. These results are
consistent with qualitative experimental measurements
reported in the literature. We discuss these consequences in
light of how the network topology and signaling character-
istics of altered (mutant) cell lines are shaped differently in
relationship to native cell lines.
Keywords—Epidermal growth factor receptor, Phosphoryla-
tion kinetics, Molecular dynamics, Molecular docking, Sig-
nal transduction, Stochastic dynamics.
INTRODUCTION
The Erb family of receptors—the epidermal growth
factor receptor (EGFR or ErbB1 or HER1), ErbB2 (or
HER2), ErbB3, and ErbB4—activates a multi-layered
network mediating crucial pathways leading to cell
proliferation, diﬀerentiation, migration and altered
metabolism,18,29,53,72 in response to activation of the
receptor by the epidermal growth factor (EGF),
transforming growth factor-a (TGF-a), and several
other related peptide growth factors.18
Erb family of receptors are receptor tyrosine kinases
(RTKs); RTKs are transmembrane glycoproteins with
a cysteine rich ligand-binding extracellular domain, a
transmembrane domain important in dimerization,
and an intracellular tyrosine kinase domain with a
tyrosine rich C-terminal tail.29,53 Activation of the li-
gand-binding domain by an extracellular ligand leads
to homodimerization or heterodimerization among the
members of the Erb family. The process of ligand-in-
duced dimerization is now quite well understood,
based on crystallographic studies.8,25 Precisely how
this ligand-induced dimerization event is coupled to,
and leads to, activation of the intracellular tyrosine
kinase domain has also emerged from recent crystal-
lographic studies.75 The crystal structure of the
EGFRTK domain was ﬁrst published in 2002, both
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alone and in complex with an inhibitor erlotinib,63 and
displayed several unique features. While structural
studies of the kinase domains from other RTKs (and
protein kinases in general) have shown them to be
catalytically inactive until an activation event such as
ligand-induced dimerization causes them to become
autophosphorylated within the activation loop29 and
subsequently become locked into a characteristic
‘active’ conformation,47 members of the EGFR family
appear to be unique in not requiring activation loop
phosphorylation27 for their activity. The crystal
structure of an unphosphorylated form of the EGFR
kinase domain was found to be constitutively locked in
the ‘active’ conﬁguration.63 In a recent pioneering
crystallographic study, it is suggested that the kinase
domain of the EGFR is regulated by a direct allosteric
stabilization of the ‘active’ conformation:75 speciﬁ-
cally, the kinase–kinase contact through an asymmet-
ric dimer interface allosterically promotes the active
conformation. Indeed, such an interface is inferred
from (and experimentally realized by) the presence of a
high concentration of the kinase domain in the crys-
tals. The study also reported a crystal structure of the
V924R mutant of EGFRTK in an inactive form which
aligned closely with a previously solved structure of
wildtype EGFRTK bound to the inhibitor lapatinib.71
The mutation replaces a hydrophobic residue at the
dimer interface with a charged group thereby destabi-
lizing the dimer interface. As a consequence, the EG-
FRTK domain retains its inactive state and relaxes
into an alternative crystallographic lattice which does
not support the activating asymmetric dimer interface.
It is well established that alteration or over expres-
sion of EGFR and ErbB2—two (of 4) members of the
ErbB family of RTKs—is correlated with a variety of
clinical cancers.43,58 Hence, small molecule RTK
inhibitors for EGFRTK and ErbB2 RTK are also of
signiﬁcant interest as cancer therapeutic drugs. Small
molecule tyrosine kinase inhibitors (e.g., anilinoqui-
nazoline compounds such as geﬁtinib and erlotinib),
which are ATP analogues,2,3,34,46,51 have been shown
to exhibit growth inhibitory effects against a wide
variety of human tumors.13–17 The RTK inhibition
approach has shown promise in some clinical trials,
but results have been quite mixed.19 In particular,
despite the promise in a small (demographic) sub-
population with signiﬁcantly advanced disease, clinical
responses to geﬁtinib and erlotinib varied among
population samples. Recently, somatic mutations
L834R, L837Q, G685S, del L723-P729 ins S (there is
an alternate clinical numbering scheme used in the
literature with an offset of 24 residues according to
which these mutations are denoted by L858R, L861Q,
G719S, del L747-P753 ins S) in the EGFRTK domain
were reported to correlate with the clinical response of
geﬁtinib and erlotinib.9,38,42,48 In vitro, these EGFR
mutants demonstrated enhanced tyrosine kinase
activity in comparison to wildtype EGFR and
increased sensitivity to inhibition.3,12,20,21,42,48,49,61
Although, the underlying biochemical basis involv-
ing the drug sensitivity to the mutations is still not
clear, the remarkable sensitivity of cell lines carrying
geﬁtinib sensitizing mutants appears not to be centered
around inhibitor or ATP binding aﬃnities, but rather
on other biochemical mechanisms regulating the
EGFRTK activity and EGF-mediated signaling.28 In a
recent review, the ErbB signaling network is likened to
a bow-tie-conﬁgured, evolvable network, displaying
modularity, redundancy, and control circuitry.18
Under this framework, identifying the role and sig-
niﬁcance of drug sensitizing mutations of ErbB
receptors would require a systems level understanding
of the signaling network.31–33 This would prove to be
of enormous value in effectively designing multikinase
inhibitors in development for cancer therapy to target
many points along the signaling pathway simulta-
neously.28,35 Evidence emerging from biochemical
studies points to differential phosphorylation rates
associated with different tyrosine phosphorylation sites
in the receptor.1,36,61,70 Moreover, recent structural
studies have indicated that the clinically identiﬁed
mutations are able to alter the regulatory elements
within the receptor such as bypassing the dimer-med-
iated activation step leading to constitutive activity.
Therefore, implications of the effect of such mutations
on preferential signaling can be crucial in shaping the
signaling response in altered cell lines derived from
cancer patients.
In this article, we adopt a multiscale modeling
approach (see Flowchart 1 and Table 1) to study the
dimer-mediated receptor activation characteristics of
EGFRTK. Through these modeling approaches, we
are able to extend the prior modeling of EGF-mediated
signal transduction by considering speciﬁc EGFRTK
docking interactions mediated by differential binding
nm~µm
µs~s 
Å~nm
fs~ns 
µm
ms~s 
Molecular dynamics 
(MD) 
simulations 
Signal transduction 
Free energy docking 
Generalized Langevin dynamics, 
Kinetic Monte Carlo
FLOWCHART 1. Scheme for hierarchical multiscale simula-
tions.
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and phosphorylation of different C-terminal peptide
tyrosines on the RTK tail. By modeling signal ﬂows
through branching pathways of the EGFRTK resolved
on a molecular basis, we are able to transcribe the
effects of molecular alterations in the receptor (e.g.,
mutant forms of the receptor) to differing kinetic
behavior and downstream signaling response.
OVERALL SUMMARY OF METHODS
Our multiscale modeling strategy is depicted in the
Flowchart 1 and Table 1, (here we provide a brief
overview; detailed description is available in the sup-
plementary information S1.1 to S1.6): our hierarchical
scheme involves molecular dynamics (see also Section
S1.1), free energy docking (see also Section S1.2), hy-
brid spatial and stochastic modeling69 (see also Sec-
tions S1.3 and S1.4), and their integration with existing
deterministic network models of EGFR-mediated
signal transduction (see also Section S1.5). Model
approximations and scope are discussed in S1.6.
Molecular Dynamics (MD, see also S1.1)
Dynamics trajectories of fully atomistic, explicitly
solvated systems of wildtype and L834R mutant
EGFRTK are obtained and analyzed for speciﬁc sta-
bilizing interactions such as hydrogen bonds and salt-
bridges.
Molecular Docking (see also S1.2)
Molecular docking is used to predict ligand bind-
ing in the absence of a ligand-bound crystal structure
and functional aﬃnity data. We employ AutoDock,
an automated docking tool designed to predict how
small molecules, such as substrates or drug candi-
dates, bind to a receptor of known 3-dimensional
structure.45 The binding free energy is calculated
based on the intermolecular energy between protein
and ligands and torsional and solvation free energy of
the ligands.45 We perform a global conformational
search using a multiple conformation docking strat-
egy, in which the protein ﬂexibility is taken into
account implicitly.
Signal Transduction (see also S1.3)
EGF stimulation in a cell results in the simultaneous
activation of multiple pathways that are functionally
interlinked.36,53,54 In the kinetic model we have em-
ployed, signaling through the EGFR is modeled by
combining three published models and augmented by
our own set of reactions and calculations (Section S1.3,
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Differential Receptor-Mediated Signaling in EGFR
Figs. S1 and S2). Phosphorylation and docking reac-
tions are modeled according to Kholodenko et al.;37
the MAP kinase pathway reactions are modeled after
Schoeberl et al.;57 Akt and PI3K activation are incor-
porated into the model as described in Brown et al.7
The similar parameterization and topology in these
models allowed us to construct a consistent, stable, and
comprehensive system with results in good agreement
with published experimental data.52 Seventeen of these
reactions are novel to this work and represent en-
hanced molecular resolution and detail in EGFR
activation, phosphorylation, and docking reactions
(Fig. 1 and Table 2). A detailed description of these
reactions is provided in Sections S1 and S2. Using the
system model, we calculate the state levels of well-
known downstream indicators of cell growth and
proliferation, such as phosphorylated ERK and Akt.
Each output state is quantiﬁed according to peak re-
sponse, total (integrated) state level, and the time
elapsed until peak response.
Intramolecular Diﬀusional Timescales of C-terminal
Tail Tyrosines in Auto- and Trans-phosphorylation (see
also S1.4)
Auto- as well as trans-phosphorylation of speciﬁc
tyrosine sites in the C-terminal tail of the receptor in-
volves diﬀusion of the particular tyrosine residue in the
C-terminal tail to the active site of the EGFRTK. We
model the tail diﬀusion as a freely joined chain (FJC)
consisting of Kuhn segments.22 The diffusion coefﬁ-
cient of the tyrosine residue is then calculated using a
reptation model22 (see S1.4). The reciprocal of the
diffusional time of a speciﬁed tyrosine residue to reach
the active site is taken as the kon for substrate binding.
Spatial Stochastic Model for Endocytotic Vesicle
Nucleation (see also S1.5)
Clathrin mediated endocytosis is a major mecha-
nism for the down regulation of activated receptor
proteins. The assembly of a clathrin coat proceeds via
a polymerization of clathrin trimers,55 which is
observed to coat the endocytotic vesicle. However, it is
believed that the clathrin coat alone may not be
capable of inducing the required curvature in the
membrane. Another protein, epsin, in fact plays a
crucial role in inducing the curvature of the mem-
brane.24,26 The protein epsin has binding sites in the
clathrin lattice and also directly interacts with the
membrane. This dual interaction together with the
dual interaction of an adaptor protein Ap180 with
clathrin and the membrane (Ap180 tethers the clathrin
coat to the membrane) is believed to induce the vesicle
nucleation and anchor the clathrin lattice to the bud-
ding vesicle. Recently, we developed the KMC-TDGL
(kinetic Monte Carlo- time-dependent Ginzburg Lan-
dau) heterogeneous multiscale approach for studying
membrane dynamical processes by combining two
different phenomenological theories.69 Simulations
performed using this approach yields the time evolu-
tion of the membrane undulations and deformation in
response to the diffusion of membrane bound epsins
and a timescale for the nucleation of an endocytotic
vesicle. We calculate the timescale for epsin-induced
endocytotic vesicle nucleation from our membrane
simulations performed using the KMC-TDGL
approach.69 We combine this timescale for nucleation
with the timescales for signal transduction calculated
using the network simulations (Section S1.3) to esti-
mate an overall timescale for phosphorylated receptor
internalization.
FIGURE 1. Phosphorylation model for EGFR. (v1) EGF binds reversibly to EGFR, which increases the receptor’s affinity for other
ligand-bound receptors (v2). Basal levels of spontaneous dimerization also occur (v3, v4; not shown). ATP binds reversibly to the
catalytic site of the receptor (v5). The transient ATP-bound EGFR must then encounter a free unphosphorylated peptide on either
cytoplasmic tail in a diffusion-limited step (v8–v11). (v12) The receptor catalyzes autophosphorylation at either Y1068 or Y1173 (for
clarity, only the Y1068 site is shown). Reactions with an asterisk denote more than one reaction involving similar kinetics but
differing substrates (see Table 2) .
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RESULTS
Dimer Mediated Activation of EGFRTK
We performed two 10 ns molecular dynamics (MD)
simulations of the EGFRTK system in the active and
the inactive conformations, respectively. Based on a
comparison of the crystal structures—active: erlotinib-
bound, wildtype,63 AMP-bound wildtype;75 inactive:
lapatinib-bound wildtype,71 V924R mutant75—we
conclude that the conformational switching from an
inactive to an active conformation involves a rotation
of the aC-helix of EGFRTK, and the shifting of the
activation loop (A-loop) residues to make way for
peptide and ATP binding. The recent study of Kuriyan
et al.75 has implicated a dimer-mediated activation
mechanism for the EGFRTK. That is, loss of inter-
actions upon RTK dimerization leads to switching of
the conformational state of the enzyme from inactive
to active conformations. On this basis, we hypothesize
that speciﬁc interactions (H-bonds and salt-bridges)
between the residues of the aC-helix and those of the
A-loop need to re-organize in the course of the con-
formational switching from inactive to active states. To
elucidate the nature of these interactions, a hydrogen
bond analysis focusing on the residues surrounding the
A-loop, aC-helix, catalytic loop, and nucleotide-bind-
ing loop was carried out using CHARMM6 and
VMD30 programs. The MD trajectories were ﬁrst
analyzed in CHARMM with a hydrogen bond cutoff
of 2.4 A˚ and a cutoff angle of 150. We generated a list
of hydrogen bonds that were present in at least 60% of
the trajectory. These hydrogen bonds were then visu-
alized in VMD and any non-signiﬁcant bonds were
removed to reveal the stabilizing H-bonds. During the
H-bond analysis, acidic and basic residues formed
strong hydrogen bonds, similar to salt-bridges. The
A-loop and aC-helix conformations were stabilized by
internal hydrogen bonds (i.e., both the residues par-
ticipating in the hydrogen bond are within the loop/
helix), as well as external hydrogen bonds (i.e., one
residue is in the loop/helix, the other is not). The res-
idues participating in these stabilizing interactions are
predominantly acidic and basic residues. A compari-
son of the speciﬁc interactions showed that the number
of external interactions stabilizing the A-loop and aC-
helix in the active conformations far out-numbered
those in the inactive conformations (see Fig. 2 and
Table 3). Intriguingly, the small number of stabilizing
interactions holding the kinase in the inactive are
predominantly located proximal to the dimer-interface
residues (Table 3), which lends further credibility to
the allosteric activation mechanism75 of the wildtype.
Namely, that loss dimer-interface residues will alter the
surrounding stabilizing bond network, which likely
leads to the destabilization of the inactive conforma-
tion and triggers the conformational shift to the active
conformation.
Constitutive Activation of the L834R Mutant
The clinically relevant mutations del724-729, and
L834R are structurally in distinct parts of the enzyme
but overall both lead to enhanced activity.10,42,48,61
Our delineated pattern of stabilizing interactions in
Table 3 serves as a platform for unifying the effects of
these mutations at a structural level. The small
number of stabilizing interactions holding the kinase
in the inactive conformation also overlaps with the
residues associated with several clinically relevant
mutations. The deletion mutant interferes directly
TABLE 2. Reaction mechanisms and parameterization for EGFR phosphorylation reactions.
Reaction Mechanism Parameter values Reference
v1 [EGFR] + [EGF] Ð [EGFR:EGF] kf = 3 10)7 M)1 s)1 kr = 3.8 10)3 s)1 Kholodenko et al.37
v2 [EGFR:EGF] + [EGFR:EGF] Ð [EGFR2] kf = 1 10)7 M)1 s)1 kr = 0.1 s)1 Kholodenko et al.37
v3a [EGFR] + [EGFR] Ð [EGFR2] kf = 1 10)7 M)1 s)1 kr = 110)3 s)1 Kholodenko et al.37, see S1.3
v5b [EGFR2] + [ATP] Ð [EGFR2:ATP] Km = 2.410)8 M)1 Brignola et al.5
v8c [EGFR2:ATP] Ð [EGFR2:ATP:Y1068] kf = 6.51105 s)1 kr = 769 s)1 Fan et al.23, see S1.3
v10d [EGFR2:ATP] Ð [EGFR2:ATP:Y1173] kf = 1.98105 s)1 kr = 48.1 s)1 Fan et al.23, see S1.3
v12e [EGFR2:ATP:Y1068] ! [EGFRY1068P2 ] kcat = 0.29 s)1 Fan et al.23
v14f [EGFR2:ATP:Y1173] ! [EGFRY1173P2 ] kcat = 0.25 s)1 Fan et al.23
v16g [EGFRY1068P2 ] ! [EGFR2] Vmax = 4.5 10)7 M)1 s)1 Km = 5.0 10)8 M Kholodenko et al.37
a An identical rate equation was employed for spontaneous dimerization of EGFR and EGFR:EGF (v4).
b Identical rate equations were employed for ATP binding to EGFR2
Y1068 (v6) and EGFR2
Y1173 (v7).
c An identical rate equation was employed for Y1068 binding to EGFR2
Y1173-P:ATP (v9).
d An identical rate equation was employed for Y1173 binding to EGFR2
Y1068-P:ATP (v11).
e An identical rate equation was employed for phosphorylation of EGFR2
Y1173-P:ATP:Y1068 (v13).
f An identical rate equation was employed for phosphorylation of EGFR2
Y1068-P:ATP:Y1173 (v15).
g Identical rate equations were employed for dephosphorylation of EGFR2
Y1173-P (v17) and EGFR2
Y1173-P (v18).
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with the dimer interface and the R substitution of L
at 834 as well as R substitution of Q in 837 desta-
bilizes the speciﬁc (external H bonds) interactions
associated with A-loop and aC-helix in the inactive
but not the active conformations. Thus, these muta-
tions have a deleterious effect (see Table 3) in stabi-
lizing A-loop and aC-helix conformations in the
inactive state, hence stabilizing the active conforma-
tion. Indeed, in one of our MD trajectories initiated
from the active conformation of the wildtype mono-
mer RTK, we observed the motion of the enzyme
towards the inactive state in 10 ns. In this case, a key
interaction between two residues in the aC-helix and
the A-loop (salt-bridge between GLU851 and
LYS734, see also Table 3) was broken. In stark
contrast, a 12 ns MD trajectory of the L834R mutant
system (under similar conditions) stayed stable in the
active conformation. The collective evidence from
these observations points to a constitutively active
L834R mutant RTK system (i.e., activated in mono-
mer and dimer states in the presence or in the absence
of an EGF ligand) and a dimer-mediated activation
of wildtype RTK (i.e., activated only in the dimer
state in the presence of the EGF ligand).
Experimental observation of constitutive activation
in the geﬁtinib-sensitive EGFR mutants has been
recorded independently in several studies, which report
signiﬁcantly elevated basal phosphorylation (in the
absence of the stimulating ligand) of the mutant sys-
tems in comparison to the wildtype.10,11,48,61
Ligand and Substrate Binding Aﬃnities for EGFRTK
We determine the ATP and erlotinib binding modes
and binding aﬃnities based on our multiple confor-
mations docking strategy (Section S1.2) and analyze
several low-energy clusters of ligand conformations.
For both wildtype and L834R mutant EGFRTK sys-
tems, one lead erlotinib binding conformation is found
to be closely aligned with that in the crystal structure:
the hydrogen bonds between the N1 of the quinazoline
and Met769 are present and so is the interaction be-
tween Thr766 and the quinazoline nitrogen atom (N3).
The binding modes for ATP and erlotinib are also
consistent with the existing pharmacophore model for
ATP binding to kinases.66,67,74 Signiﬁcantly, a second
binding mode, which has a higher afﬁnity to the mu-
tant kinase L834R, is revealed in our calculations. This
mode still blocks the ATP binding pocket and in
addition shows an additional interaction between er-
loitnib and the R834 residue. The effect is a higher
calculated binding afﬁnity for erlotinib binding to
L834R ()9.4±0.4 kcal/mol) in comparison to wild-
type ()7.3±0.5 kcal/mol).
In order to explore the C-terminal peptide-sub-
strate-bound pre-catalytic conformation, we also dock
FIGURE 2. Visualization of the stabilizing residues external to A-loop and aC-helix (shown in blue), dimer interface residues
(shown in red) and clinical mutations (shown in green) of both the active (panel a) and inactive (panel b) EGFR tyrosine kinases.
The A-loop is highlighted in sky blue while the aC-helix is shown in purple, the remainder of the protein is colored orange. The
external stabilizing residues for the EGFR tyrosine kinases are numbered from 1–40, with 1–27 corresponding to residues in the
active state while 28–40 correspond to the stabilizing residues in the inactive state. The stabilizing residues that are potentially
affected by dimerization are highlighted in red boxes, and the residues that are potentially affected by the clinical mutations are
highlighted in green boxes (See also Table 3). The inactive conformation has fewer stabilizing bonds holding the conformation
stable: 13 stabilizing residues as opposed to 27 stabilizing residues. Therefore, the loss of interactions triggered by either mutation
or dimerization will have a greater effect upon the stability of the inactive kinase and allow a conformation change. The numbered
labels correspond to the residue numbers as follows: 1:672 2:679 3:721 4:728 5:732 6:734 7:737 8:738 9:740 10:741 11:743 12:744
13:745 14:808 15:810 16:812 17:832 18:834 19:836 20:838 21:840 22:843 23:845 24:848 25:851 26:867 27:932 28:738 29:740 30:742
31:744 32:753 33:812 34:813 35:834 36:836 37:846 38:848 39:851 40:865.
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EGFRTK substrate peptides to the catalytic site. First,
we focus on an optimal peptide sequence EEEYFEL as
a control. This optimal sequence is selected for a
maximal value in kcat/KM among EGFRTK substrate
peptides.60 Based on 500–1000 different genetic algo-
rithm runs for docking of this peptide to EGFRTK, we
select the best binding conformation for binding as one
that yields the lowest binding free energy simulta-
neously with the correct orientation for the tyrosine
binding into the active site. The latter criterion is
essential in ensuring that kcat is not signiﬁcantly com-
promised in obtaining a stronger binding. We depict in
Fig. 3, the peptide conformation bound to the active
site, which is seen to be ideally poised for a two-metal-
ion catalyzed phosphoryl transfer from ATP to the
bound tyrosine:44,64 i.e., the relative positions of the
ATP, Mg2+ ions, and the catalytic aspartates are in
good alignment. Encouraged by this result, we per-
formed peptide docking simulations for two substrate
peptides (each being seven amino acids long) corre-
sponding to the Y1068 (VPEYINQ) and Y1173
(NAEYLRV) sites of the C-terminal tail for both
wildtype and L834R mutant structures. Based on a
similar criteria of lower binding free energy and opti-
mal catalytic geometry, we calculated the peptide
binding afﬁnity corresponding to sites Y1068 and 1173
for wildtype and L834R mutant systems. Upon
mutation, the calculated KM for the Y1068 peptide
decreased 20-fold (calculated DDG [wildtype ﬁ
L834R] = )2.2 kcal/mol), while the calculated KM for
the Y1173 peptide increased 4-fold (calculated DDG
[wildtype ﬁ L834R] = +0.9 kcal/mol). Analysis of
the binding modes reveals that the relative alignment
of the tyrosine with respect to the catalytic site is ideal
(2.2 A˚ in the observed distance n between Tyr OH
oxygen and Asp 813 Od2) for the two peptide tyrosines
binding to wildtype, with the two mutant systems
showing a 0–1.5 A˚ deviation. The differences can
translate into differences in kcat values associated with
the tyrosine phosphorylation. Assuming a harmonic
energy proﬁle along the reaction coordinate n with a
force constant Kn, the work done in reducing this
distance is given by 1/2Knn
2. The value of Kn is
obtained by recording the ﬂuctuations of n in the MD
simulations (Kn = kBT/rn
2 = 0.77 kcal/mol/A˚2 for
the wildtype and 1.01 kcal/mol/A˚2 for L834R), where
rn is the standard deviation associated with the ﬂuc-
tuations in n in the trajectories). The normalized values
of kcat/KM can then be compared for the four systems
Table 3. External stabilizing interactions in inactive and
active conformations, dimer-interface residues, and clinical
mutations.
alphaC-helix A-loop 
Stabilizing Salt Bridges 
Active  Inactive Active  Inactive 
2 1 3 2 
Stabilizing H-bonds 
5 2 7 3 
alphaC-helix (Residues 729 to 743) 
Active Inactive 
Stabilizing Salt Bridges 
 GLU 734    LYS 851   GLU 738     LYS 836     
 GLU 738    LYS 721             
Stabilizing H-bonds 
 ASN 732 HN   SER 728 O  TYR 740 O    
SER 744 
HN,HG1
 GLU 738 
OE1,2   PHE 832 HN  MET 742 O   LEU 753 HN    
 TYR 740 O   SER 744 HG1      
 VAL 741 O   VAL 745 HN            
 ALA 743 O   LEU 679 HN     
Activation Loop (Residues 831 to 852) 
 Active Inactive 
Stabilizing Salt Bridges 
 LYS 843    ASP 932   LYS 836  GLU 738  
 GLU 848    ARG 812   GLU 848  ARG 865  
LYS 851  GLU 734    
Stabilizing H-bonds 
 PHE 832 HN  
 GLU 738 
OE1,2
LEU 834 
HN ASP 813 OD1
 LEU 834 O  
 ARG 812 
HH12
HIS 846 
NE2     ARG 865 HH11    
 LYS 836 HZ2  ASP 737 OD2 LYS 851 O 
ARG 812 
HH11,21
 LYS 836 
O,HN
 VAL 810 
HN,O     
 LEU 838 HN   ARG 808 O            
 ALA 840 HN   GLY 672 O            
 TYR 845 
O,HN
 TYR 867 
HN,O     
Dimer Interface Residues  
L680 I682 L736 L758 V762 I917 Y920 M921 V924 M928 
Clinical Mutations 
L834R del723-728 S744I L837Q E685G G695S 
FIGURE 3. Binding modes for ATP (cyan) and the optimal
peptide sequence (yellow) in the EGFRTK domain. The
geometry of the active site is consistent with that prescribed
for an ideal two-metal-ion catalyzed mechanism and reveals a
state that is poised for the phosphoryl transfer reaction. The
alignment of the two divalent Mg2+ ions as well as the catalytic
aspartates D813 and D831 are also shown.
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at the same value of n = 2.2 A˚); the relative increase
in kcat/KM: 1068 for the L834R in comparison to the
wildtype is 20-fold (increase by 1-order of magnitude),
while the relative decrease for the 1073 is 200-fold
(decrease by 2-orders of magnitude). This differential
sensitivity translates into differences in phosphoryla-
tion of the associated tyrosine sites, which ultimately
leads to differential signaling and down stream acti-
vation in the EGFR network: the Y1173-phosphory-
lation is associated Shc mediated ERK activation
and Y1068-phosphorylation is associated with Akt
activation.36,61
Time-scales Associated with Diﬀusion of Substrate
Tyrosines Binding Prior to Auto- and Trans-
phosphorylation and with Endocytotic Vesicle
Nucleation
C-terminal Tail Diﬀusion
Using the method outlined in Section S1.4, we cal-
culate the diﬀusional time scale for each of the seven
tyrosine residues present on the C-terminal tail of
EGFRTK to reach the active site (Table 4). The
timescales for diffusion are in ls and not very different
for the different tyrosine sites to bind to the active site
prior to auto- (head) or trans- (tail) phosphorylation.
For each case, the reciprocal of the corresponding
timescale is taken as the on-rate (kon) of the tyrosine
binding to the active site. The off-rate is calculated as
koff = kon exp(+DG/kBT), where DG is the binding
free energy of the substrate to the active site; here it is
assumed that the binding process is diffusion-limited
with no signiﬁcant additional barriers. The values for
DG for each C-terminal tyrosine is obtained from the
analogous data on peptide substrate afﬁnities KM
published in the literature:5,23 DG/kBT = )ln(KM).
These calculated values are used in the model for signal
transduction described in Section 2.3 and provided in
Table 2.
Endocytotic Vesicle Nucleation
In our earlier work, we identiﬁed diﬀerent regimes
conducive to nucleation of an endocytotic vesicle by
exploring a range of parameters associated with the
membrane adsorbed proteins, such as surface density
of the protein on the membrane, and the intrinsic
curvature of the membrane induced by the protein–
membrane interaction.69 Here, we report our results
speciﬁcally for epsins interacting with the membrane.
Consistent with the experimental values of Ford et al.,
we assume that the intrinsic membrane curvature
induced by the epsin molecules falls in the range of
10 lm)1. We further assume that the distance from a
given epsin molecule that this curvature effect decays is
four times the epsin diameter. A depiction of our
ﬁndings for an epsin surface density (on the mem-
brane) of 60 per lm2 is given in Fig. 4, in which in the
time-course of 250–400 s, the nucleation of a vesicle is
observed (see snapshots in panels B–D). Panels E and
F provide the corresponding spatial and orientational
correlations.69 The necessary condition for nucleation
is the persistence of orientational (hexagonal) ordering
of the membrane-adsorbed epsin molecules (see cap-
tion).69 Our results have suggested an interesting
mechanism for the epsin-mediated membrane invagi-
nation. Namely, the invagination occurs through a
nucleation event, which involves the co-localization
and hexagonal ordering of several epsin molecules on
the membrane. Based on our results (Fig. 4), the
timescale for nucleation of such an event is 250–400 s.
As described in Section 2.3, receptor activation,
which is eventually followed by receptor internaliza-
tion (via endocytosis), results in triggering many signal
transduction cascades, one of which being the PLCc
pathway.4,72 The PLCc pathway is accompanied by a
transient release of calcium ions from intracellular
stores. Models for the transient release of calcium have
been developed on the basis of several published
experimental studies.39,59 We work under the hypoth-
esis that the signal transduction in the endocytosis
pathway is coupled to membrane deformation via two
functional interactions: (1) the direct induction of
curvature via the interaction of the membrane lipids
with epsin;24,50,56,62 and (2) through the assembly of
the clathrin coat,56,73 which is triggered by an increase
in the local concentration of Ca2+ ions released in the
PLCc pathway.4 In the latter case, above a threshold
value of Ca2+ concentration the clathrin monomers
spontaneously self-assemble to form a lattice.56,73 This
leads to the following mechanism for endocytosis. The
transient increase in calcium concentration at the site
of the activated receptor helps promote clathrin poly-
merization and coat assembly. The adapter protein
Ap180 tethers the clathrin lattice on the membrane.
TABLE 4. Diffusional time for C-terminal tyrosines to reach
the active site of EGFRTK.
Tyrosine
residue
Diffusional time to the active site (ls)
Head EGFRTK
(auto-phosphorylation)
Tail EGFRTK
(trans-phosphorylation)
Y992 0.34 0.65
Y1045 1.72 2.54
Y1068 2.64 3.68
Y1086 3.49 4.7
Y1101 4.26 5.61
Y1148 7.26 9.08
Y1173 9.16 11.22
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The vertices of the hexagonal lattice of the clathrin
coat provide binding sites for epsins. Thus, in the
vicinity of the activated receptor, the membrane ad-
sorbed epsins assume a spatial conformation with
persistent orientational correlations induced by the
clathrin lattice. This provides the condition for a
nucleation event leading to formation of the endocy-
totic vesicle. (We note that according to this mecha-
nism, unactivated receptors can also internalize;
however, in the absence of the transient calcium surge,
which only occurs upon receptor activation, the
clathrin coat assembly may represent a slower step).
An estimate for the timescale of receptor internali-
zation s(internalization) is therefore obtained by the
sum of timescales for receptor phosphorylation at
Y1045, PLCc activation, calcium release, clathrin coat
assembly, and nucleation of epsin-mediated vesicle
formation.
Diﬀerential Signaling through EGFRTK
By employing the deterministic model described in
Section 2.3 (see Figs. 1 and S1, Table 2) we have cal-
culated transient evolution of the EGF-mediated sig-
naling network under a variety of initial conditions
and parameter values. In particular, we have focused
on two pools of normal ([EGFR] = 100 nM or 33,000
receptors per cell) and over expressed ([EGFR] =
2000 nM or 660,000 receptors per cell) EGFR con-
centrations, each in the absence (serum starved,
[EGF] = 0 nM) and presence (serum cultured,
[EGF] = 8 nM) of the EGF ligand. A typical time-
course resulting from our network simulations is
provided in Fig. S3, in which the kinetics of phos-
phorylation of EGFRTK and down-stream markers
Ras, Raf, PLCc, PI3K, and Akt are depicted. Since
our molecularly resolved model (Fig. 1) is currently
focused on differential signaling through Y1068 and
Y1173 phosphorylation sites of EGFRTK, we track
the integrated response of ERK and Akt phosphory-
lation levels in our simulations. Each output state was
quantiﬁed according to the peak level of phosphory-
lation over the simulated time of 1000 s. Speciﬁcally,
we perform a two-dimensional scan over kcat/KM val-
ues associated with Y1068 and Y1173 phosphorylation
in which the respective kcat/KM values are allowed to
deviate from their default (wildtype) value over a log-
arithmic range of ﬁve log units. The result is a two-
dimensional matrix in which each element represents
output from a single simulation involving a unique pair
of parameters (see Fig. 5).
The simulated response of the EGFR network also
enables us to estimate a timescale for receptor inter-
nalization s(internalization). The typical timescale for
EGFRTK phosphorylation is in the range of 10 s,
while that for PLCc activation is 50 s (see Figs. S3 and
S4). The calcium release from intracellular stores
through the activation of IP3R (IP3 receptors) is re-
FIGURE 4. (a) Depiction of the system of epsin molecules interacting with the membrane. (b–d) Snapshots of the system at
different time points (the epsin positions are not shown for clarity). The blue regions are recessed and red regions are elevated in
the membrane. The nucleation of a budding vesicle in the membrane is evident in panel. (d, e) Spatial correlation function for the
membrane adsorbed epsins. (f) Orientational correlation function for the membrane adsorbed epsins. The correlation functions are
provided for 3 simulation runs at different epsin densities (q*, dimensionless) and values of the induced curvature (c0 expressed
in lm)1). The value of a dimensionless density (q* = 0.024 corresponds to 60 epsins per lm2. The snapshots correspond to the red
symbols in panels e and f (q* = 0.024 and c0 = 10 lm
)1). For this case, there is persistence of orientational correlations (hexagonal
ordering), see panel f. For the other two cases in panels e and f (for which snapshots are not shown), no nucleation and no
significant orientational ordering is observed.
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ported to occur within a short timescale of 10 s.59
While the timescale for clathrin coat self-assembly
under high calcium concentration is not known, it is
assumed here that this is a rapid process. According to
our results from the spatial stochastic simulations
(Section 3.4), the epsin mediated endocytotic vesicle
nucleation in the presence of the clathrin coat is cal-
culated to occur in a timescale 250–400 s. Further,
assuming that the stabilization of the budding endo-
cytotic vesicle and the vesicle pinch-off process cata-
lyzed by dynamin are not rate-limiting, the estimated
time for vesicle internalization upon EGF ligand
binding is 450 s (8 min). We note that these time-
scales from our simulations are ball park estimates and
we have not yet attempted a careful comparison with
timescales from experimental measurements.
DISCUSSION AND CONCLUSIONS
Based on an integration of a large body of knowl-
edge accumulated over the years, the modular nature
of EGFR-mediated signaling has become appar-
ent.18,31 Through a hierarchical multiscale modeling
scheme, we have realized a molecular resolution to this
system-level view, which can potentially augment our
predictive as well as comprehensive capabilities and
rationalize the changes in early signaling characteris-
tics of altered and mutant cell lines. Our overall ﬁnd-
ings are summarized below.
Analysis of stabilizing interactions in our molecular
dynamics simulations have corroborated a dimer-
mediated activation mechanism for the EGFRTK.
That is, loss of key stabilizing interactions in the
inactive conformation of the kinase upon dimerization
results in destabilizing the inactive state and triggering
a conformational change to the active state. Moreover,
our results point to a constitutively active L834R
mutant. That is, even in a monomer state, the RTK of
the L834R mutant system is stabilized in an active
conformation and can trigger signaling through
the EGFR network by auto-phosphorylation of its
C-terminal tail tyrosine residues in an EGF (ligand)
independent manner. These results are consistent with
the existing biochemical data which have10,42,48,61,75
qualitatively shown that the phosphorylation of C-
terminal tail tyrosines of the L834R mutant in the
absence of EGF stimulation is comparable to wildtype
values in the presence of EGF stimulation at EGF
concentrations of 30–100 ng/ml.
Our results from the free energy docking simula-
tions suggest enhanced binding of the inhibitor erl-
otinib to the L834R mutant system in comparison to
wildtype binding. Our results also reveal preferential
binding and phosphorylation of certain C-terminal
tyrosine substrates (but not others) to the L834R
mutant in comparison to the wildtype: that is, the
calculated change in the turn over rate (kcat/KM) upon
the L834R mutation is markedly different for the
Y1173 peptide in comparison to the Y1068 peptide.
This results in a differential sensitivity at the receptor
level. Speciﬁcally, the estimated increase in kcat/KM
for the Y1068 peptide is 10-fold in comparison to a
decrease of 100-fold for the Y1173 peptide. Thus,
FIGURE 5. Calculated ERK and Akt phosphorylation levels in units of nM (peak-levels over the time course of 1000 s) under
serum starved (EGF)) and serum cultured (EGF+) conditions for cell types with normal EGFR expression and EGFR over
expression. In each panel the Y1173 rate of phosphorylation (kcat/KM) is varied along the x-axis (value relative to wildtype EGFRTK)
and the Y1068 rate of phosphorylation (kcat/KM) is varied along the y-axis. In each panel, the blue circle denotes the wildtype levels
and the green square denotes those relevant to the L834R mutant cell lines.
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we expect to see a net increase in phosphorylation of
Y1068 and a net decrease in phosphorylation of
Y1173 for the L834R mutant, in comparison to
wildtype levels. The biochemical results of Sordella
et al.61 and Chen et al.10 corroborate this view qual-
itatively; in these studies, the immunoblots measuring
the degree of phosphorylated receptor at the Y1173
site show a modest decrease for the L834R mutant
in contrast to a strong increase for the Y1068 site,
both in comparison to their respective wildtype
measurements.
Our systems level simulation illustrates how the
altered aﬃnities at the receptor level for the wildtype
and L834R translates into changes in the downstream
response. In Fig. 5, we explored how the variation in
Y1173 and Y1068 phosphorylation affects the peak
responses of ERK and Akt for two different EGFR
concentrations, each in the absence or presence of
EGF stimulation. The calculated responses for the
wildtype values are highlighted by the blue circles at
the origin of each of the panels. The responses for
L834R are identiﬁed by the green square centered at a
(kcat/KM)/(kcat/KM)wildtype value of 1/100 ()2 in log10
units) for Y1073 and 10 (+1 in log10 units) for Y1068.
Owing to the constitutively active characteristic of the
L834R mutant, the signals relevant for the L834R
system (even in the absence of EGF) are analogous to
those in the panels with EGF stimulation. As indicated
by the color maps in these two scans, increasing the
degree of phosphorylation of the Y1173 site (positive
x-direction) leads to an overall increase in ERK
response. This ﬁnding is consistent with our model
which is based on Y1173 being an important docking
site for the Shc and Grb-2 adaptors that lead to Ras
activation and subsequent Erk phosphorylation. For
normal EGFR expression, the calculated ERK re-
sponse in the absence of EGF is low for the L834R
mutant (0.01 nM) but negligible (zero) for the wild-
type. In the presence of EGF the ERK response for
L834R is 7-fold lower than that for the wildtype. For
over expressed EGFR, the ERK activation is 7-fold
higher in L834R compared to wildtype both in the
presence as well as in the absence of EGF stimulation.
Thus, ERk stimulation is higher in EGFR over-
expressed cells. The Akt response relative to the wild-
type is 2-fold higher for the mutant cells under no EGF
stimulation and about the same under EGF stimula-
tion for normal EGFR expression. The Akt response
does not seem to be affected by mutation for high
EGFR expression either in the presence or absence of
EGF.
Our calculated responses for ERK and Akt signaling
for normal EGFR expression agree with the qualitative
experimental observations of Sordella et al.61 and
Tracy et al.:65 namely, that the ERk stimulation levels
decrease and the Akt levels are maintained for the
mutant cells with normal EGFR expression levels. This
preferential activation of Akt in L834R mutant cell
lines observed in these experiments is consistent with
the systems level predictions from our simulations.
Moreover, our calculations predict that the preferential
Akt activation is not featured in EGFR over-expressed
cells.
In light of the overall agreement between simula-
tions and experiment, we can begin to explore the
origins of inhibitor sensitivity in L834R mutant cell
lines. The enhanced sensitivity of erlotinib to L834R
mutant arises from a combination of several eﬀects:
(1) the mutant system has a higher binding aﬃnity to
the inhibitor; (2) the constitutive activity of L834R
deems the mutant to be a more potent target for
therapeutic inhibition; (3) The diﬀerences in the pre-
dicted downstream response (between the wildtype
and the mutant) accounted for by early signaling
events can potentially lead to a divergent long-term
behavior in the two systems causing a diﬀerential
sensitivity to inhibition. More conclusive inferences
from our modeling results can only be obtained after
we consider the eﬀect of other receptor states
(namely, one in which Y845 is phosphorylated) and
interactions with other Erb partners (see below), on
down-stream signal response.
In conclusion, we have described the role of a
hierarchical multiscale computational approach in
resolving at a molecular level the systems-level model
of EGFR-mediated signal transduction, to help
rationalize the collective information emerging from
biochemical, cell biology, and clinical studies. Our
approach enables us to transcribe diﬀerences in
molecular mechanisms as well as functional activity
originating at the single molecule level into tangible
diﬀerences in early signaling events. Therefore, sub-
ject to the well appreciated modeling limitations
discussed in Section S1.6, this predictive capability is
useful in diﬀerentiating signaling characteristics of
mutant cell lines from the native wildtype case. This
molecular-based reﬁnement of the overall EGFR
signal transduction model is a ﬁrst attempt at
untangling the diﬀerential nature of early signaling
events triggered by receptor activation and their
consequences in shaping the signal transduction in
altered cell lines derived from diﬀerent pathologies.
A complete model, which is currently being pursued,
will not only require resolving the diﬀerential char-
acteristics of all of the tyrosine phosphorylation sites
in EGFRTK and their associated substrate recogni-
tion properties in EGFR, but also the extension to
other Erb family members in the context of homo-
and hetero-dimers. Transactivation of EGFR occur-
ring through ligand-induced receptor heterodimer-
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ization68 combined with a potential for differential
signaling adds a palette of ﬁner control elements in
the ErbB-family signaling network. Indeed, recent
studies have identiﬁed possible mutations in ErbB2
that may correlate with drug sensitivity in different
cancers.40,41 The computational tools described here
are ideal for assessing the likely effect of novel
EGFR and ErbB2 mutations and determining whe-
ther the drug-sensitizing mutations implicated in non-
small-cell lung cancer also occur in other cancers. We
believe that our model driven approach will in the
long-term signiﬁcantly impact the optimization of
future small molecule therapeutic inhibition strategies.
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